Abstract
Summary
LPI (LP Information)' newest research report, the “Cystic Fibrosis Drugs Industry Forecast” looks at past sales and reviews total world Cystic Fibrosis Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Cystic Fibrosis Drugs sales for 2023 through 2029. With Cystic Fibrosis Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cystic Fibrosis Drugs industry.
This Insight Report provides a comprehensive analysis of the global Cystic Fibrosis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cystic Fibrosis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cystic Fibrosis Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cystic Fibrosis Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cystic Fibrosis Drugs.
The global Cystic Fibrosis Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Cystic Fibrosis Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Cystic Fibrosis Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Cystic Fibrosis Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Cystic Fibrosis Drugs players cover Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Vertex Pharmaceuticals, Abbott, Anthera Pharmaceuticals, Arcturus Therapeutics and Boehringer Ingelheim, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Cystic Fibrosis Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Oral Cystic Fibrosis Drugs
Injection Cystic Fibrosis Drugs
Segmentation by application
Hospitals
Clinics
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Actavis
F. Hoffmann-La Roche
Gilead Sciences
Novartis
Vertex Pharmaceuticals
Abbott
Anthera Pharmaceuticals
Arcturus Therapeutics
Boehringer Ingelheim
Chiesi Farmaceutici
Corbus Pharmaceuticals
Genzyme
Insmed
Johnson & Johnson
Merck Sharp & Dohme
Neovii Biotech
Novo Nordisk
PharmaSwiss
Pharmaxis
Proteostasis Therapeutics
PTC Therapeutics
United Medical
Venus Remedies
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cystic Fibrosis Drugs market?
What factors are driving Cystic Fibrosis Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cystic Fibrosis Drugs market opportunities vary by end market size?
How does Cystic Fibrosis Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
This Insight Report provides a comprehensive analysis of the global Cystic Fibrosis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cystic Fibrosis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cystic Fibrosis Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cystic Fibrosis Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cystic Fibrosis Drugs.
The global Cystic Fibrosis Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Cystic Fibrosis Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Cystic Fibrosis Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Cystic Fibrosis Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Cystic Fibrosis Drugs players cover Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Vertex Pharmaceuticals, Abbott, Anthera Pharmaceuticals, Arcturus Therapeutics and Boehringer Ingelheim, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Cystic Fibrosis Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Oral Cystic Fibrosis Drugs
Injection Cystic Fibrosis Drugs
Segmentation by application
Hospitals
Clinics
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Actavis
F. Hoffmann-La Roche
Gilead Sciences
Novartis
Vertex Pharmaceuticals
Abbott
Anthera Pharmaceuticals
Arcturus Therapeutics
Boehringer Ingelheim
Chiesi Farmaceutici
Corbus Pharmaceuticals
Genzyme
Insmed
Johnson & Johnson
Merck Sharp & Dohme
Neovii Biotech
Novo Nordisk
PharmaSwiss
Pharmaxis
Proteostasis Therapeutics
PTC Therapeutics
United Medical
Venus Remedies
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cystic Fibrosis Drugs market?
What factors are driving Cystic Fibrosis Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cystic Fibrosis Drugs market opportunities vary by end market size?
How does Cystic Fibrosis Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cystic Fibrosis Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Cystic Fibrosis Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Cystic Fibrosis Drugs by Country/Region, 2018, 2022 & 2029
2.2 Cystic Fibrosis Drugs Segment by Type
2.2.1 Oral Cystic Fibrosis Drugs
2.2.2 Injection Cystic Fibrosis Drugs
2.3 Cystic Fibrosis Drugs Sales by Type
2.3.1 Global Cystic Fibrosis Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Cystic Fibrosis Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Cystic Fibrosis Drugs Sale Price by Type (2018-2023)
2.4 Cystic Fibrosis Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Other
2.5 Cystic Fibrosis Drugs Sales by Application
2.5.1 Global Cystic Fibrosis Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Cystic Fibrosis Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Cystic Fibrosis Drugs Sale Price by Application (2018-2023)
3 Global Cystic Fibrosis Drugs by Company
3.1 Global Cystic Fibrosis Drugs Breakdown Data by Company
3.1.1 Global Cystic Fibrosis Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Cystic Fibrosis Drugs Sales Market Share by Company (2018-2023)
3.2 Global Cystic Fibrosis Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Cystic Fibrosis Drugs Revenue by Company (2018-2023)
3.2.2 Global Cystic Fibrosis Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Cystic Fibrosis Drugs Sale Price by Company
3.4 Key Manufacturers Cystic Fibrosis Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cystic Fibrosis Drugs Product Location Distribution
3.4.2 Players Cystic Fibrosis Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Cystic Fibrosis Drugs by Geographic Region
4.1 World Historic Cystic Fibrosis Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Cystic Fibrosis Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Cystic Fibrosis Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Cystic Fibrosis Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Cystic Fibrosis Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Cystic Fibrosis Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Cystic Fibrosis Drugs Sales Growth
4.4 APAC Cystic Fibrosis Drugs Sales Growth
4.5 Europe Cystic Fibrosis Drugs Sales Growth
4.6 Middle East & Africa Cystic Fibrosis Drugs Sales Growth
5 Americas
5.1 Americas Cystic Fibrosis Drugs Sales by Country
5.1.1 Americas Cystic Fibrosis Drugs Sales by Country (2018-2023)
5.1.2 Americas Cystic Fibrosis Drugs Revenue by Country (2018-2023)
5.2 Americas Cystic Fibrosis Drugs Sales by Type
5.3 Americas Cystic Fibrosis Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cystic Fibrosis Drugs Sales by Region
6.1.1 APAC Cystic Fibrosis Drugs Sales by Region (2018-2023)
6.1.2 APAC Cystic Fibrosis Drugs Revenue by Region (2018-2023)
6.2 APAC Cystic Fibrosis Drugs Sales by Type
6.3 APAC Cystic Fibrosis Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cystic Fibrosis Drugs by Country
7.1.1 Europe Cystic Fibrosis Drugs Sales by Country (2018-2023)
7.1.2 Europe Cystic Fibrosis Drugs Revenue by Country (2018-2023)
7.2 Europe Cystic Fibrosis Drugs Sales by Type
7.3 Europe Cystic Fibrosis Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cystic Fibrosis Drugs by Country
8.1.1 Middle East & Africa Cystic Fibrosis Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Cystic Fibrosis Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Cystic Fibrosis Drugs Sales by Type
8.3 Middle East & Africa Cystic Fibrosis Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cystic Fibrosis Drugs
10.3 Manufacturing Process Analysis of Cystic Fibrosis Drugs
10.4 Industry Chain Structure of Cystic Fibrosis Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cystic Fibrosis Drugs Distributors
11.3 Cystic Fibrosis Drugs Customer
12 World Forecast Review for Cystic Fibrosis Drugs by Geographic Region
12.1 Global Cystic Fibrosis Drugs Market Size Forecast by Region
12.1.1 Global Cystic Fibrosis Drugs Forecast by Region (2024-2029)
12.1.2 Global Cystic Fibrosis Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Cystic Fibrosis Drugs Forecast by Type
12.7 Global Cystic Fibrosis Drugs Forecast by Application
13 Key Players Analysis
13.1 Actavis
13.1.1 Actavis Company Information
13.1.2 Actavis Cystic Fibrosis Drugs Product Portfolios and Specifications
13.1.3 Actavis Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Actavis Main Business Overview
13.1.5 Actavis Latest Developments
13.2 F. Hoffmann-La Roche
13.2.1 F. Hoffmann-La Roche Company Information
13.2.2 F. Hoffmann-La Roche Cystic Fibrosis Drugs Product Portfolios and Specifications
13.2.3 F. Hoffmann-La Roche Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 F. Hoffmann-La Roche Main Business Overview
13.2.5 F. Hoffmann-La Roche Latest Developments
13.3 Gilead Sciences
13.3.1 Gilead Sciences Company Information
13.3.2 Gilead Sciences Cystic Fibrosis Drugs Product Portfolios and Specifications
13.3.3 Gilead Sciences Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Gilead Sciences Main Business Overview
13.3.5 Gilead Sciences Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Cystic Fibrosis Drugs Product Portfolios and Specifications
13.4.3 Novartis Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Vertex Pharmaceuticals
13.5.1 Vertex Pharmaceuticals Company Information
13.5.2 Vertex Pharmaceuticals Cystic Fibrosis Drugs Product Portfolios and Specifications
13.5.3 Vertex Pharmaceuticals Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Vertex Pharmaceuticals Main Business Overview
13.5.5 Vertex Pharmaceuticals Latest Developments
13.6 Abbott
13.6.1 Abbott Company Information
13.6.2 Abbott Cystic Fibrosis Drugs Product Portfolios and Specifications
13.6.3 Abbott Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Abbott Main Business Overview
13.6.5 Abbott Latest Developments
13.7 Anthera Pharmaceuticals
13.7.1 Anthera Pharmaceuticals Company Information
13.7.2 Anthera Pharmaceuticals Cystic Fibrosis Drugs Product Portfolios and Specifications
13.7.3 Anthera Pharmaceuticals Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Anthera Pharmaceuticals Main Business Overview
13.7.5 Anthera Pharmaceuticals Latest Developments
13.8 Arcturus Therapeutics
13.8.1 Arcturus Therapeutics Company Information
13.8.2 Arcturus Therapeutics Cystic Fibrosis Drugs Product Portfolios and Specifications
13.8.3 Arcturus Therapeutics Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Arcturus Therapeutics Main Business Overview
13.8.5 Arcturus Therapeutics Latest Developments
13.9 Boehringer Ingelheim
13.9.1 Boehringer Ingelheim Company Information
13.9.2 Boehringer Ingelheim Cystic Fibrosis Drugs Product Portfolios and Specifications
13.9.3 Boehringer Ingelheim Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Boehringer Ingelheim Main Business Overview
13.9.5 Boehringer Ingelheim Latest Developments
13.10 Chiesi Farmaceutici
13.10.1 Chiesi Farmaceutici Company Information
13.10.2 Chiesi Farmaceutici Cystic Fibrosis Drugs Product Portfolios and Specifications
13.10.3 Chiesi Farmaceutici Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Chiesi Farmaceutici Main Business Overview
13.10.5 Chiesi Farmaceutici Latest Developments
13.11 Corbus Pharmaceuticals
13.11.1 Corbus Pharmaceuticals Company Information
13.11.2 Corbus Pharmaceuticals Cystic Fibrosis Drugs Product Portfolios and Specifications
13.11.3 Corbus Pharmaceuticals Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Corbus Pharmaceuticals Main Business Overview
13.11.5 Corbus Pharmaceuticals Latest Developments
13.12 Genzyme
13.12.1 Genzyme Company Information
13.12.2 Genzyme Cystic Fibrosis Drugs Product Portfolios and Specifications
13.12.3 Genzyme Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Genzyme Main Business Overview
13.12.5 Genzyme Latest Developments
13.13 Insmed
13.13.1 Insmed Company Information
13.13.2 Insmed Cystic Fibrosis Drugs Product Portfolios and Specifications
13.13.3 Insmed Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Insmed Main Business Overview
13.13.5 Insmed Latest Developments
13.14 Johnson & Johnson
13.14.1 Johnson & Johnson Company Information
13.14.2 Johnson & Johnson Cystic Fibrosis Drugs Product Portfolios and Specifications
13.14.3 Johnson & Johnson Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Johnson & Johnson Main Business Overview
13.14.5 Johnson & Johnson Latest Developments
13.15 Merck Sharp & Dohme
13.15.1 Merck Sharp & Dohme Company Information
13.15.2 Merck Sharp & Dohme Cystic Fibrosis Drugs Product Portfolios and Specifications
13.15.3 Merck Sharp & Dohme Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Merck Sharp & Dohme Main Business Overview
13.15.5 Merck Sharp & Dohme Latest Developments
13.16 Neovii Biotech
13.16.1 Neovii Biotech Company Information
13.16.2 Neovii Biotech Cystic Fibrosis Drugs Product Portfolios and Specifications
13.16.3 Neovii Biotech Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Neovii Biotech Main Business Overview
13.16.5 Neovii Biotech Latest Developments
13.17 Novo Nordisk
13.17.1 Novo Nordisk Company Information
13.17.2 Novo Nordisk Cystic Fibrosis Drugs Product Portfolios and Specifications
13.17.3 Novo Nordisk Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Novo Nordisk Main Business Overview
13.17.5 Novo Nordisk Latest Developments
13.18 PharmaSwiss
13.18.1 PharmaSwiss Company Information
13.18.2 PharmaSwiss Cystic Fibrosis Drugs Product Portfolios and Specifications
13.18.3 PharmaSwiss Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 PharmaSwiss Main Business Overview
13.18.5 PharmaSwiss Latest Developments
13.19 Pharmaxis
13.19.1 Pharmaxis Company Information
13.19.2 Pharmaxis Cystic Fibrosis Drugs Product Portfolios and Specifications
13.19.3 Pharmaxis Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Pharmaxis Main Business Overview
13.19.5 Pharmaxis Latest Developments
13.20 Proteostasis Therapeutics
13.20.1 Proteostasis Therapeutics Company Information
13.20.2 Proteostasis Therapeutics Cystic Fibrosis Drugs Product Portfolios and Specifications
13.20.3 Proteostasis Therapeutics Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Proteostasis Therapeutics Main Business Overview
13.20.5 Proteostasis Therapeutics Latest Developments
13.21 PTC Therapeutics
13.21.1 PTC Therapeutics Company Information
13.21.2 PTC Therapeutics Cystic Fibrosis Drugs Product Portfolios and Specifications
13.21.3 PTC Therapeutics Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 PTC Therapeutics Main Business Overview
13.21.5 PTC Therapeutics Latest Developments
13.22 United Medical
13.22.1 United Medical Company Information
13.22.2 United Medical Cystic Fibrosis Drugs Product Portfolios and Specifications
13.22.3 United Medical Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 United Medical Main Business Overview
13.22.5 United Medical Latest Developments
13.23 Venus Remedies
13.23.1 Venus Remedies Company Information
13.23.2 Venus Remedies Cystic Fibrosis Drugs Product Portfolios and Specifications
13.23.3 Venus Remedies Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 Venus Remedies Main Business Overview
13.23.5 Venus Remedies Latest Developments
14 Research Findings and Conclusion